Enliven Therapeutics (ELVN) Stock News
$ELVN · NASDAQ · 1 stories in 30 daysBORSA has published 1 story on Enliven Therapeutics (ELVN) in the past 30 days. BORSA’s news read on ELVN is bullish at 67/100, −1 over 24 hours, based on 1 company event over the past 30 days. ELVN last closed at $40.84 on Oct 12, down 10.18% over five sessions and down 24.82% over the past month. Enliven Therapeutics’ next earnings report is scheduled for Wednesday, Nov 11.
The wire on $ELVN
newest first · updated · direct subject stories onlyEnliven Therapeutics reaches FDA alignment on Phase 3 trial design for relcobatinib in CML
Enliven Therapeutics (ELVN) announced FDA alignment on the final design of the ENABLE-2 Phase 3 trial for relcobatinib in previously treated CML. The ~450-patient randomized trial compares relcobatinib to second-generation TKIs with MMR at Week 24 as primary endpoint. Company on track to initiate before year-end 2026.
bullish 80 · impact 60